GALT - 2.48 Pre-market now at 3.20/3.56 Galectin Therapeutics to Present Results from Phase 2b NASH-CX Trial on December 5, 2017 http://stockcharts.com/c-sc/sc?s=GALT&p=D&b=5&g=0&i=t32231861355&r=1512473023769 http://stockcharts.com/c-sc/sc?s=GALT&p=W&b=5&g=0&i=t35039106158&r=1512472999804